ERBB2 and cancer: The recently updated UK HER2 reporting guidelines [7] and the updated American Society of Clinical Oncology–College of American Pathologists Guideline Update [8] have recognized the importance of distinguishing the HER2-low cancers to inform therapy with trastuzumab deruxtecan.